Evidence map›Paper›PMID 34898046›Full record

ArticleCancer medicine2022

Analysis of CDK12 alterations in a pan-cancer database.

Elizabeth Pan, Angelo Cabal, Juan Javier-DesLoges, Devin Patel, Justine Panian, Suzanna Lee, Justin Shaya, Taylor Nonato, Xiaojun Xu, Tyler Stewart and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Liquid Biopsy by ctDNA in Liver Transplantation for Colorectal Cancer Liver Metastasis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elizabeth PanDivision of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.ORCID 0000-0001-7025-9104
Angelo CabalDivision of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.
Juan Javier-DesLogesDepartment of Urology, University of California San Diego, San Diego, California, USA.ORCID 0000-0003-1120-9144
Devin PatelDepartment of Urology, University of California San Diego, San Diego, California, USA.
Justine PanianDivision of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.
Suzanna LeeMoores Cancer Center, University of California San Diego, San Diego, California, USA.
Justin ShayaDivision of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.
Taylor NonatoDivision of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.
Xiaojun XuMoores Cancer Center, University of California San Diego, San Diego, California, USA.
Tyler StewartDivision of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.
Brent RoseDepartment of Radiation and Applied Sciences, University of California San Diego, San Diego, California, USA.
Ahmed ShabaikDepartment of Pathology, University of California San Diego, San Diego, California, USA.
Ezra CohenDivision of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.
Razelle KurzrockDivision of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.
Pablo TamayoDivision of Medical Genetics, School of Medicine, University of California San Diego, California, USA.
Rana R McKayDivision of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.ORCID 0000-0002-0581-7963

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
NCI NIH HHS P30 CA023100
6 · The paper itself

Abstract

backgroundCDK12 inactivation leading to increased neoantigen burden has been hypothesized to sensitize tumors to immune checkpoint inhibition. Pan-cancer data regarding the frequency of CDK12 alterations are limited. We aimed to characterize CDK12 alterations across all cancer types through real-world clinical-grade sequencing.

methodsThis was a single-center retrospective analysis of 4994 cancer patients who underwent tissue or blood genomic profiling, including CDK12 assessment, conducted as part of routine care from December 2012 to January 2020. Prevalence, clinical characteristics, and treatment outcomes of patients with tumors with pathogenic CDK12 alterations were described.

resultsIn all, 39 (0.78%, n = 39/4994) patients had pathogenic CDK12 alterations. Among CDK12-altered tumors, the most common organ site was prostate (n = 9, 23.1%) followed by colorectal (n = 5, 12.8%). Adenocarcinoma was the most common histology (n = 26, 66.7%). Median follow-up from time of diagnosis was 4.02 years. Median overall survival from time of metastasis was 4.43 years (95% CI: 3.11-5.74). Ten patients with CDK12-altered tumors received at least one immune checkpoint inhibitor-containing regimen. The majority of patients (n = 6/10, 60%) experienced an objective response. Progression-free survival for patients who had metastatic disease and received a checkpoint inhibitor-containing regimen was 1.16 years (95% CI: 0.32-2.00).

conclusionCDK12 alterations are rare events across hematologic and solid tumor malignancies. They represent a clinically distinct molecular cancer subtype which may have increased responsiveness to checkpoint inhibition. Prospective studies are warranted to investigate checkpoint inhibition in CDK12-altered tumors.

Indexed as

Cyclin-Dependent KinasesNeoplasmsData ManagementHumansMaleProstateRetrospective StudiesCDK12 protein, humanCyclin-Dependent Kinasesbiomarkerscancer geneticsclinical cancer researchgenomics

Identifiers

PMID34898046
PMCPMC8817093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.